Subscribe to RSS
DOI: 10.1055/s-2007-965050
Georg Thieme Verlag KG Stuttgart · New York
18F‐FDG‐PET (Positronenemissionstomografie) zur Differenzialdiagnostik bei simultaner Retroperitonealfibrose und Lymphknotenmetastasierung nach Ovarialkarzinom
18F‐FDG‐PET (Positron Emission Tomography) for the Differential Diagnosis of Retroperitoneal Fibrosis and Lymphogenous Metastasis after Ovarian CancerPublication History
eingereicht 9.11.2006
revidiert 25.1.2007
akzeptiert 30.1.2007
Publication Date:
29 March 2007 (online)
![](https://www.thieme-connect.de/media/gebfra/200703/lookinside/thumbnails/10.1055-s-2007-965050-1.jpg)
Zusammenfassung
Die retroperitoneale Fibrose (M. Ormond) stellt eine seltene Differenzialdiagnose zur Lymphknotenmetastasierung des Ovarialkarzinoms dar. Wir berichten über eine Patientin, bei der im Rahmen der CT-Diagnostik die differenzialdiagnostische Verdachtsdiagnose einer Retroperitonealfibrose (RPF) gestellt und letztendlich über gezielte Stanzbiopsie histologisch gesichert werden konnte. Über eine zusätzliche Ganzkörper-PET-Untersuchung konnte eine simultane Lymphknotenmetastasierung des Ovarialkarzinoms nachgewiesen und die entsprechende Second-Line-Chemotherapie eingeleitet werden. Die ansonsten bei Retroperitonealfibrose mit Harnabflussstörung indizierte, häufig extensive Chirurgie zur Ureterolyse konnte so vermieden werden. Zur Differenzierung unklarer retroperitonealer Läsionen nach gynäkologischen Malignomen sollte für eine sinnvolle Therapieplanung die PET-Diagnostik genutzt werden.
Abstract
Retroperitoneal fibrosis (M. Ormond) is a rare differential diagnosis for lymphogenous retroperitoneal metastasis of ovarian cancer. We describe a case of a histologically proven retroperitoneal fibrosis (RPF) after tumor recurrence of primary adenocarcinoma of the ovary. By additional PET examination the simultaneous RPF and tumor recurrence could be diagnosed and therapeutic decisions for a second line chemotherapy could be made on the basis of minimally invasive procedures, and an otherwise extensive surgical intervention for ureterolysis could be avoided. PET should be used for optimized therapeutic management in a case of a retroperitoneal tumor formation of unclear origin during the follow up of gynecological malignancy.
Schlüsselwörter
Retroperitonealfibrose - 18F‐FDG‐PET - Ovarialkarzinomrezidiv
Key words
Retroperitoneal fibrosis - 18F‐FDG‐PET - ovarian cancer recurrence
Literatur
- 1 Auer J, Berent R, Hinterholzer G. et al . [Retroperitoneal fibrosis as the etiology for recent onset of abdominal pain, nausea and vomiting-a rare and easily missed differential diagnosis]. Acta Med Austriaca. 2000; 27 163-167
- 2 De Luca S, Terrone C, Manassero A. et al . Aetiopathogenesis and treatment of idiopathic retroperitoneal fibrosis. Ann Urol (Paris). 1998; 32 153-159
- 3 Adab F A, Mould J J. Carboplatin and retroperitoneal fibrosis. Clin Oncol (R Coll Radiol). 1992; 4 327-328
- 4 Katz R, Golijanin D, Pode D. et al . Primary and postoperative retroperitoneal fibrosis - experience with 18 cases. Urology. 2002; 60 780-783
- 5 Zimny M, Siggelkow W. Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol. 2003; 15 69-75
- 6 Yen R F, Sun S S, Shen Y Y. et al . Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res. 2001; 21 3691-3694
- 7 Picchio M, Sironi S, Messa C. et al . Advanced ovarian carcinoma: usefulness of [(18)F]FDG‐PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2003; 47 77-84
- 8 Hofer C, Kubler H, Hartung R. et al . Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol. 2001; 40 481-487
- 9 Strauss L G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996; 23 1409-1415
- 10 Sironi S, Messa C, Mangili G. et al . Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004; 233 433-440
- 11 Chim C S, Liang R, Chan A C. Sclerosing malignant lymphoma mimicking idiopathic retroperitoneal fibrosis: importance of clonality study. Am J Med. 2001; 111 240-241
- 12 Vaglio A, Greco P, Versari A. et al . Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol. 2005; 23 231-234
- 13 Kubota K, Yamada K, Yoshioka S. et al . Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F‐18 fluorodeoxyglucose. Clin Nucl Med. 1992; 17 361-363
- 14 Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun. 2004; 25 651-656
- 15 Zhuang H, Pourdehnad M, Lambright S. et al . Dual time point 18F‐FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42 1412-1417
- 16 Heidenreich A, Derakhshani P, Neubauer S. et al . [Treatment outcomes in primary and secondary retroperitoneal fibrosis]. Urologe A. 2000; 39 141-148
- 17 Kardar A H, Kattan S, Lindstedt E. et al . Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol. 2002; 168 550-555
- 18 Oosterlinck W, Derie A. New data on diagnosis and medical treatment of retroperitoneal fibrosis. Acta Urol Belg. 1997; 65 3-6
- 19 Loffeld R J, van Weel T F. Tamoxifen for retroperitoneal fibrosis. Lancet. 1993; 341 382
- 20 Puce R, Porcaro A B, Curti P. et al . Treatment of retroperitoneal fibrosis with tamoxifen: case report and review of literature. Arch Esp Urol. 2000; 53 184-190
- 21 Tonietto G, Agresta F, Della Libera D. et al . Treatment of idiopathic retroperitoneal fibrosis by tamoxifen. Eur J Surg. 1997; 163 231-235
- 22 Benson J R, Baum M. Tamoxifen for retroperitoneal fibrosis. Lancet. 1993; 341 836
Dr. Carolin Nestle-Krämling
Frauenklinik der Heinrich-Heine-Universität Düsseldorf
Moorenstraße 5
40225 Düsseldorf
Germany
Email: cnk@uni-duesseldorf.de